Brief: Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results For Palazestrant
22/10/2023 07:57
Oct 22 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY ANNOUNCES POSITIVE PHASE 2 MONOTHERAPY
CLINICAL
STUDY RESULTS FOR PALAZESTRANT
* RESULTS SUPPORT CONTINUED DEVELOPMENT OF PALAZESTRANT IN
OPERA-01 MONOTHERAPY PHASE 3 PIVOTAL TRIAL
* ACROSS ALL 86 HEAVILY PRETREATED PATIENTS, MEDIAN PFS WAS
4.6
MONTHS WITH A CBR OF 40%
Source text for Eikon: ID:nGNX4tY2Wn
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Oncology
See all newsBrief: Olema Pharmaceuticals Changes Corporate Name To Olema Oncology, Effective Today
Olema Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary
Olema Pharma Q3 net loss widens on higher costs
Brief: Olema Pharmaceuticals Q3 Net Income USD -73.599 Million
Olema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary